You are here:
ESPRIT: Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments
In this research consortium, we are part of three clinical multicenter studies in which we investigate innovative treatments for schizophrenia (exercise, endocannabidiol) or for patients with high-risk for schizophrenia (acetycystein). Within these and another psychotherapy projects we also collect ecological momentary assessment (EMA) data.
PI Berlin (Henrik Walter, Andreas Heinz)
(PIs ESPRIT: Andreas Meyer-Lindenberg, Manheim and Peter Falkai, Munich)
Team: Sebastian Mohnke, Wladimir Tantchik, Bob Vogel
Funding: BMBF 01EE1407G (02/2015-01/2019), AVD (02/2018-01/2019)